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Traditional growing rod versus
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for treatment of early onset scoliosis:
Cost analysis from implantation till
skeletal maturity
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and Kenneth Man Chee Cheung2
Abstract
Purpose: To compare the yearly cost involved per patient in the use of magnetically controlled growing rod (MCGR) and
traditional growing rods (TGRs) in the treatment of early onset scoliosis (EOS) and to assess the overall cost burden of
MCGR with reference to patient and health-care infrastructure. Methods: For a hypothetical case of a 5-year-old girl
with a diagnosis of EOS, a decision-tree model using TreeAge Software was developed to simulate annual health state
transitions and compare the 8-year accumulative direct, indirect, and total cost among the four groups: (1) dual MCGRs
with exchange every 2 years, (2) dual MCGRs with exchange every 3 years, (3) TGR with surgical distraction every year,
and (4) TGR with surgical distraction every 6 months. Base-case values and ranges of clinical parameters reflecting
complication rate after each type of surgical distraction were determined from a review of literature and expert opinion.
Government gazette and expert opinion provided cost estimation of growing rods, surgeries, surgical complications, and
routine follow-up. Microsimulation of 1000 individuals was conducted to test the variation in total direct costs (in 2016
Hong Kong dollars (HKD)) between individuals, and estimated the standard deviations of total direct costs for each group.
Results: Over the projected treatment period, indirect costs incurred by patients and family were higher for the MCGR
as compared to the TGR. However, the total costs incurred by MCGR groups (group 1: HKD164k; group 2: HKD138k)
were lower than those incurred by TGR groups (group 3: HKD191k; group 4: HKD290k). Although the accumulative
costs of three groups (TGR with distraction every year and MCGR replacing every 2 and 3 years) were approaching each
other in the first 2 years after initial implantation, at year 3 the accumulative cost of MCGR exchange every 2 years was
HKD36k more than the yearly TGR surgery due to the cost of implant exchange. The cost incurred by both the MCGR
groups was less than that incurred by the TGR groups from year 4 to skeletal maturity. Conclusions: The use of dual
MCGRs, regardless of its 2- or 3-year exchange, was only cost saving and less expensive than the dual TGRs for EOS
treatment from the fourth year of continuous treatment. Despite higher patient-related costs during MCGR treatment, it
is important to consider the reduced risks and mental burden suffered by these children during repeat surgeries. With
improved knowledge of the costs associated with long-term MCGR use, better constructed cost-effectiveness studies can
be performed in the future.
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Introduction
In this modern age, increased health-care costs influence
the type of medication or device that is available to health-
care providers. A new drug or medical device may be
effective clinically in treating a certain condition, but occa-
sionally the cost to the patient and establishment may be
too significant and becomes a deterrent to health-care pro-
viders to implement. It is necessary for health administra-
tors and government officials to see not only data proving
the superiority of a certain treatment method in terms of
clinical effectiveness but also cost saving to push forward
any new drug or medical device. Hence, health-care eco-
nomics is an important factor that the industry and clinician
must consider prior to testing or initiating any new treat-
ment. Health-care economics is, in particular, a significant
factor in guiding decision-making of spine surgery. The
field of spine surgery is evolving at a rapid pace with new
and possibly improved implant systems introduced into the
market. Thus, spine surgeons must be able to balance the
necessity of certain devices with their cost.
Early onset scoliosis (EOS) is one spine condition that
requires special attention. The associated spinal deformity
occurs in young children and if left untreated, the deformity
progresses and cause cosmetic disfigurement, poor pul-
monary development, and overall poor quality of life.1–8
Traditional growing rods (TGRs), which require open sur-
gery under anesthesia every 6–12 months for manual rod
distraction, have been the mainstay surgical option avail-
able for gradual correction of scoliosis in young children.9–
11 Implantation of these TGRs allows regular distractions
for spine growth and thus avoids spinal fusion.9,10,12,13
However, if we assume a 5-year-old girl with EOS is
implanted with the TGR, she may require up to 16 length-
ening procedures if skeletal maturity is at 13 years. This
imposes significant psychological and financial burden to
the child and family including repeat hospital admissions,
visits to clinics and therapists, and increased rate of anes-
thetic and wound complications with distraction sur-
gery.1,2,11 The overall wound complication rate from
TGR is 16%, which increases by 24% during each addi-
tional surgery.2
The magnetically controlled growing rod (MCGR) is
growing in popularity as it avoids repeat manual distrac-
tions with the TGR by utilizing an external magnet to drive
its internal distraction device.14 This allows outpatient dis-
tractions with the patient awake and under constant neuro-
logical monitoring. Thus, the MCGR is a preferred
alternative to the TGR. Studies have shown that the MCGR
has similar clinical effectiveness in curve correction,15–18
better long-term length gains,19 and can provide safe gra-
dual correction of severe deformities in young patients with
EOS.20 In addition, distractions can be done at more fre-
quent and regular intervals to better mimic normal growth.
Although more frequent imaging may be required to mon-
itor these increased distractions, radiation-free techniques
like the ultrasound can be used as proxy.21
Being able to perform more frequent distraction proce-
dures, however, may have potential drawbacks of increased
traveling and time off of work for the parents. Furthermore,
the cost of the MCGR is significant due to the manufactur-
ing cost of its internal magnet/actuator as compared to
more simple or “home-made” constructs used for TGRs.
Yet, a possible cost-saving value of the MCGR is to reduce
the number of operations. This has the benefit of reduced
anesthetic and surgical risks, cost for surgical consumables,
and duration of intensive care stay. Several cost analysis
studies22–24 have attempted to compare the TGR and
MCGR in terms of associated costs and have found the
MCGR to be cost saving in comparison to the TGR. How-
ever, several flaws of these studies include short-term
follow-up with limited outlook on the risk of complications
with prolonged use of the MCGR and the cost of rod
exchanges. Multiple MCGRs are necessary to be implanted
over the course of an EOS patient’s treatment since the
housing portion of the rod can only accommodate 4.8 cm
of distraction, far less than the expected spine growth in a
child.14 Furthermore, implant-related complications such
as rod fracture, implant dislodgment, and proximal junction
failure have been reported.14 The authors have the longest
experience of using the MCGR with follow-up of subjects
until skeletal maturity and rod removal or spinal
fusion.14,17 Hence, it is the opportune moment for us to
present a thorough cost analysis comparing TGR and
MCGR based on our long-term data. The aim of study as
such is to identify the direct and indirect costs associated
with TGR and MCGR use with respect to the patient and
the health-care infrastructure.
Methods
Model structure and setting
For a hypothetical 5-year-old girl with EOS, a decision tree
with individual patient microsimulation model was devel-
oped to simulate annual health state transitions and to com-
pare the 8-year accumulative cost among four commonly
adopted strategies based on the authors’ experience: (1)
dual MCGRs with exchange every 2 years, (2) dual
MCGRs with exchange every 3 years, (3) dual TGRs with
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surgical distraction every year, and (4) dual TGRs with sur-
gical distraction every 6 months. Only dual rods were con-
sidered as they have superior outcomes compared to single
rods and thus is generally preferred.9,17 The microsimulation
(or first-order Monte Carlo simulation) model started with a
decision mode from which one of the four groups (two
MCGRs and two TGRs) originated. Within each decision
mode, microsimulation generated a hypothetical group of
EOS using 1000 patients and tracked them until the end of
simulation. Based on the results of these 1000 patients, mean
value and standard deviation of accumulative costs per strat-
egy were calculated. A time horizon of 8 years was used
(initial surgery at 5 years to projected maturity at 13 years) to
cover the whole treatment trajectory between strategies with
respect to the types of growing rods and the frequency of
distraction surgery. No cross-over between strategies (i.e.
individual opt out or transferred from one strategy to
another) was allowed in this model. Full compliance was
assumed for all surgical and nonsurgical treatments and for
routine follow-up assessments. The structure of the costing
model is depicted in Figure 1.
Literature search were performed to identify the types
and risks of surgical complications to be included in this
model after review of the authors’ own experience. The
probabilities of complications after distraction were
obtained from a study that specifically compared compli-
cation rates between MCGR and TGR for EOS patients.25
Surgical complications after distraction were single event
in nature and were classified into three major subtypes:
superficial infection, deep infection, and implant pullout.
More than one complication might occur during specific
interventions. Since the study25 did not capture surgical
complications other than those three major subtypes, no
other surgical complications were assumed to occur after
surgery. In particular, rod fracture was not included as it
was due to a mechanical weakness in the rod design that has
been addressed in the latest generation of MCGRs.14 No
surgical mortality and all-cause mortality were accounted
for in this model. Probabilities at base-case scenario are
reported in Table 1.
Direct costs
The 8-year cumulative costs per strategy were aggregated
based on the health-care provider’s and societal perspec-
tives and expressed as 2016 Hong Kong dollars (HKD)
(converting to US dollars (USD) with exchange rate pegged
at US$1 ¼ HK$7.8). Medical costs were considered from
the health-care provider’s perspective, while both medical
and patient time costs were considered from the societal
viewpoint. Relevant unit costs of the growing rod, anchor,
cross-connector, and cross-link implants were retrieved
from the rod manufacturer and cost reports from the
Department of Orthopaedics and Traumatology, the Uni-
versity of Hong Kong and its affiliated hospitals: The
Duchess of Kent Children’s Hospital and Queen Mary
Hospital. As health care in Hong Kong is a government-
based public system, all direct costs are charged to the
institution while individual patient need to pay only a daily
flat rate as cost recovery for health-care system.
In our center, the CD Horizon® LegacyTM system from
Medtronic® is the most commonly used instrumentation sys-
tem for scoliosis surgery. For the purposes of this study, we
adopted the costs of using this system for the anchors, cross-
connectors, and rods for TGR and the anchors for the
MCGR. The routine instrumentation construct used was four
anchors at the upper end and four anchors at the lower end.
For simplicity of calculation, all anchors analyzed in this
study consisted of pedicle screws only. For dual TGR, two
rod connectors were used to connect the four rods. However,
only the cost of two rods were used for analysis since the
length of one manufactured rod was usually adequate to be
cut into two rods for creating the TGR construct. In the TGR
group, patients were assumed to have one to two surgeries
every year depending on the frequency of reoperation and
stop surgery at year 7 or the date of projected skeletal matu-
rity. By repeating surgery every 2 years, the patients in the
MCGR group were assumed to undergo surgery at initial
year, year 2, year 4, and year 6. By repeating surgery every
3 years, the patients in the MCGR group were assumed to
undergo surgery at initial year, year 3, and year 6.
Costs associated with each surgery accounted for spinal
cord monitoring, duration of operating theater use, man-
power (nurse/anesthetist), intraoperative and follow-up
X-ray imaging, outpatient visits, and length of hospitaliza-
tion (general ward) of a total of 3 days inclusive of one
night at the intensive care unit (ICU). Costs associated with
hospitalizations, outpatient, and physiotherapy visits were
based on the latest charges to nonentitled persons for use of
health services in the hospital authority/governing health-
care body (as cost recovery charges for health services), as
published in 2013 government gazette.26 Based on the
authors’ practice, the number of routine follow-up visits
given to TGR every year, TGR every 6 months, and MCGR
groups was 2, 4, and 12 per year, respectively. This was
based on one postoperative visit for wound assessment and
one preoperative visit for operation consent and imaging
between each TGR distraction, and monthly outpatient dis-
traction visits for the MCGR. Costs accrued for surgical
complication were estimated from expert opinion on the
average health resources utilized for managing individual
complications. For superficial infection, the cost of 2-week
oral antibiotics was considered. For deep infection, the
costs incurred included one surgical debridement (involv-
ing anesthetist, theater cost, and personnel), 1 week hospi-
talization (one night at ICU), antibiotics (1 week
intravenous antibiotics followed by 5-week oral antibio-
tics), and wound dressing. For implant pullout, the cost
incurred included the cost of four screws (for revision of
the upper anchors that were the common site of failure),
imaging, operating theater, and hospital stays of 3 days
(inclusive of one night at ICU). Table 2 outlines the unit
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cost for each service component associated with the use of
growing rods in EOS patients. The consumption of health-
care resources in this study was based on the authors’ expe-
rience in managing EOS patients. Undoubtedly, the number
of items used and the cost per item would be subjected to
individual center and region’s variability.
Indirect costs
Indirect costs were valued based on a human capital
approach theory. Lost productivity due to the caring for
EOS patients was counted as parental work loss because
these patients are by definition less than 18 years old for the
Figure 1. Schematic presentation of the magnetically controlled growing rod and traditional growing rod treatment costing model with
four strategies. Microsimulation of 1000 individuals was conducted for each study from implantation till skeletal maturity.
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entire simulation. Parents were assumed to take either half-
day or full-day off from work, equivalent to approximately
4 hours or 8 hours spent accompanying the EOS patient,
respectively. Surgical treatment was assumed to take one
full day for preoperative assessment and one full-day post-
operatively to accompany the patient before discharge,
while outpatient visits for routine follow-up and distraction
were assumed one half-day off from work. Monetary val-
ues were estimated with all working hours lost due to the
treatment and their related transportation and gross hourly
salary of the working population in Hong Kong. Gross
hourly salary in Hong Kong working population aged from
15 to 65 was quoted from Census and Statistics Department
of Hong Kong Government27 and adjusted to year 2016.
Base-case and sensitivity analyses
To take time preferences into account, future direct and
indirect costs were annually discounted at a rate of 3%,
recommended by established guidelines28 and frequently
adopted in health economic evaluation applied to the set-
ting of Hong Kong.29 Accumulative costs for each strategy
from both patient and institution perspective were calcu-
lated. TreeAge software Pro version 2016 (Treeage Soft-
ware, Inc., Williamstown, MA) was used for development
of decision tree and microsimulation analyses. As for base-
case scenario, MCGR group was considered as the cost-
saving or dominant strategy when compared to TGR group
if accumulative costs for both groups 1 and 2 were less than
those for groups 3 and 4.
Sensitivity analysis was performed to assess uncertainty
and robustness of model parameters such as the discount
rate and time horizon. Each model parameter had varied
theoretical possible range, whereas the value of other para-
meters kept constant. Threshold of parameter value at
which the accumulative costs of MCGR and TGR groups
were the same was captured. Range of parameter values at
which either MCGR or TGR group was cost saving was
provided.
Results
The medical costs accrued in the initial surgery per patient
in MCGR and TGR groups were HKD134652 and
HKD27528, respectively. In this 8-year period, the total
costs for the MCGR group repeating surgery every 2 years
and every 3 years were HKD1635650 and HKD1383033,
respectively, while the total costs for TGR group repeating
surgery every 1 year and every 6 months were
HKD1914117 and HKD2897967, respectively. From the
health-care provider’s perspective, both strategies for TGR
(groups 3 and 4) cost more than the two strategies for
MCGR (groups 1 and 2) despite the incorporation of
increased indirect costs with more frequent follow-up visits
and time off from work for the MCGR. Among the strate-
gies in the MCGR group, the cost for patients repeating
surgery every 2 years is slightly more than those repeating
surgery every 3 years, due to the discounting factor having
a greater reduction in the costs in the later years which is
contributed by the difference in final surgery dates. The
MCGR groups with repeat surgery every 2 years and every
3 years underwent the final surgery at year 5 and 7, respec-
tively. Hence, it involved less costs in the former group
compared to the latter group. Table 3 summarizes the
direct, indirect, and total costs for each strategy considered
in this costing analysis. The accumulative costs for each
strategy from institution and patient perspectives are listed
in Table 4.
Sensitivity analysis was performed by varying the model
parameters to verify the uncertainty and robustness of con-
clusions. However, no change in the conclusion was
observed by unit costs of treatment and discount rate.
Figure 2 shows the direct costs for each strategy at each
year cycle. Although the accumulative costs of three groups
(TGR repeating surgery every 1 year and the two MCGR
groups) were approaching each other in the first 2 years
after initial implantation and distractions, the accumulative
cost per patient in the yearly TGR distraction group was
higher than that of MCGR groups in year 2 and from year 4
onward. The accumulative cost per patient in MCGR with
exchange every 2 years (HKD808120) was only HKD36k
more than that of TGR repeating surgery every 1 year
(HKD771497) in year 3 when the former group had implant
exchange. The threshold for being cost saving for both
MCGR groups was 4 years after initial surgery.
Discussion
This cost-analysis study has significant implications on the
future of EOS management. Despite the high cost of the
MCGR device, the overall resource consumption is less
than that of the TGR in this simulation but only if the entire
Table 1. Clinical parameters associated with magnetically
controlled growing rod (MCGR) and traditional growing rod
(TGR) in early onset scoliosis patients.
Clinical Parameters Base case (%) Reference
Risk of surgical complication after
MCGR
70.00 Teoh 2016
Superficial infection (per surgical
patient)
0.00 Teoh 2016
Deep infection (per surgical patient) 7.78 Teoh 2016
Implant pullout (per surgical patient) 62.22 Teoh 2016
Risk of surgical complication after
TGRa
77.78 Teoh 2016
Superficial infection (per surgical
patient)
31.11 Teoh 2016
Deep infection (per surgical patient) 19.44 Teoh 2016
Implant pullout (per surgical patient) 35.00 Teoh 2016
MCGR: magnetically controlled growing rod; TGR: traditional growing
rod.
aPatients in TGR group may have at least one surgical complications.
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duration of treatment spans more than 4 years. The cost of
the MCGR dwarfs any individual consumable for TGR
treatment but the cumulative cost of more frequent sur-
geries over the course of an 8-year treatment is overall
costlier. This finding holds true even with more frequent
exchanges of the MCGR (every 2 years). Furthermore, our
findings are in line with the international literature related
to cost comparison between MCGR and TGR groups. At
the health technology assessment submitted to UKNational
Institute for Health and Care Excellence (NICE),30 the
MCGR generates cost savings of GBP12,077 per patient
when compared to TGR over 6 years, while the MCGR
results in cost saving of US$40,000 when compared to
TGR over 5 years from the US payer’s perspective.31
The health-care system in Hong Kong is a
government-based public platform where the govern-
ment covers all costs incurred at a flat rate. Hence, it
is important for our model to analyze the costs to health
care and patient separately. This is visibly different from
the health-care systems represented in France,22 United
Kingdom,24 and the United States.23 It is also important
to note that unlike Charroin et al.22 and Rolton et al.,24
our model is based on an entire treatment plan for an
EOS patient from initial surgery to skeletal maturity. In
addition, with our longer experience with the MCGR
device, this model is more realistic in terms of the tim-
ing of rod exchange and the costs incurred for each
complication.
Table 2. Unit cost ($HKD) for each service component associated with the use of growing rod in early onset scoliosis patients.
Unit cost ($HKD) Reference
Growing rod
Single MCGR 58,500 Ellipse Technologies/Nuvasive®
Dual MCGRs 117,000 Ellipse Technologies/Nuvasive®
Traditional growing rod 27,528 Total cost for construct
Medtronic® CD Horizon® LegacyTM system
Legacy 27,528 Medtronic® CD Horizon® LegacyTM system
Cross link 1500 Medtronic® CD Horizon® LegacyTM system
Rod 3090 Medtronic® CD Horizon® LegacyTM system
Set screws 2696 Medtronic® CD Horizon® LegacyTM system
Screw 13,456 Medtronic® CD Horizon® LegacyTM system
Rod cross connector 6786 Medtronic® CD Horizon® LegacyTM system
Surgical treatment
Spinal implants used 35,000 Department of O&T, HKU
Spinal cord monitoring 629 Department of O&T, HKU
Intensive care unit length of stay 23,000 Government Gazette
General ward length of stay 4680 Government Gazette
Operating theatre
Salary of staff 37,989.75 Department of O&T, HKU
Drugs 3792.62 Department of O&T, HKU
Consumables 2733.99 Department of O&T, HKU
Dressing 325.16 Department of O&T, HKU
Radiology
Imaging examination 566 Department of O&T, HKU
Outpatient visits
Salary of staff 1,859.34 Department of O&T, HKU
Consultation 1110 Government Gazette
Routine follow-up visit
Outpatient visits
Salary of staff 464.83 Department of O&T, HKU
Consultation 1110 Government Gazette
Physiotherapy visit 1050 Department of O&T, HKU
PþO visit
Corset (first time) 3170 Department of O&T, HKU
Adjustment (first time) 700 Department of O&T, HKU
Ultrasound (staff cost for MCGR only)
Complications from Surgical treatment
Infection
Superficial 221.20 Department of O&T, HKU
Deep 96,640.40 Department of O&T, HKU
Implant pullout 84,967.50 Department of O&T, HKU
PþO: prosthetics and orthotics; MCGR: magnetically controlled growing rod; TGR: traditional growing rod; HKD: Hong Kong Dollar; O&T: ortho-
pedics and traumatology; HKU: The University of Hong Kong.
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The cost saving threshold for both MCGR strategies
compared to the TGR occurs at 4 years after initial surgery
in our model. Beyond this point, each groups’ cumulative
cost continue to increase at its own projection, with the
TGR remaining higher than MCGR for the rest of the treat-
ment period. This takes into account a consistently higher
annual indirect cost of MCGR than TGR at all times.
Hence, the cost-saving benefit of MCGR is sustainable and
remains true in the long run as supported by this model.
Also, it is worth noting that MCGR exchanged at every 3
years becomes the most cost-saving approach from year 3
onward, and it continues to be the least costing approach
until the end of treatment. Upon further examination of the
MCGR groups, the differentiation of costs between a 2-
year and 3-year exchange strategy is most definite and is
best illustrated 5 years into the patient’s treatment where
the 2-year strategy overtakes a 3-year strategy in cost. This
suggests that a substantial period of treatment with the
MCGR is needed to be cost saving comparing to the TGR.
The two major cost items in EOS management as evi-
denced in this model are implant cost and intensive care
stay. Regardless of possible interregional variations in the
cost of the MCGR, the device is still an expensive cost unit
and thus interval rod exchanges are a significant impact to
the overall cost. The main reason for interval MCGR
exchange is the maximum capacity of 4.8 cm distracted
length allowed in the rod’s housing unit. There has been
discussion of whether retraction of the distracted length and
extending the construct length with an additional rod and
rod connectors can avoid the purchase of a new MCGR.
However, whether this affects the outcome of successful
distraction or the complication rate is unknown and thus not
a factor included in this cost model.
Despite the high cost of the MCGR, the costs of opera-
tive consumables and postoperative intensive care stay
were higher for the TGR and thus the balance was main-
tained. Partly contributed by the similarly high complica-
tion rate of MCGR treatment, differences in cost between
TGR and MCGR are not as apparent until the fourth year of
treatment. Nevertheless, the reported MCGR complication
rates used in our analysis are only based on limited evi-
dence supported by case series.25 These studies are limited
in sample size and follow-up duration. Since the MCGR
has only been in use for less than a decade, long-term
follow-up studies are lacking, and we expect more refined
complication rates to be available for future cost-analysis
Table 4. Accumulative institution, patient, and total costs for each growing rod strategy.
Year
after
initial
surgery
MCGR (Reop in 2 years)
in $HKD
MCGR (Reop in 3 years)
in $HKD
TGR (Reop in 1 year)
in $HKD
TGR (Reop in 6 months)
in $HKD
Institution
cost
Patient
cost
Total
cost
Institution
cost
Patient
cost
Total
cost
Institution
cost
Patient
cost
Total
cost
Institution
cost
Patient
cost Total cost
1 268,134 120,970 389,104 268,134 120,970 389,104 173,581 29,265 202,846 349,037 30,754 379,790
2 342,165 123,861 466,026 342,165 123,861 466,026 458,332 30,710 489,042 800,299 33,644 833,943
3 680,518 127,603 808,120 419,168 126,667 545,835 739,383 32,113 771,497 1,242,633 36,451 1,279,084
4 749,924 130,328 880,252 742,343 130,300 872,643 1,018,898 33,476 1,052,374 1,672,151 39,176 1,711,327
5 1,059,795 133,855 1,193,649 808,177 132,946 941,123 1,288,848 34,799 1,323,646 2,095,884 41,821 2,137,705
6 1,131,940 136,423 1,268,363 878,139 135,514 1,013,653 1,558,170 36,083 1,594,253 2,512,353 44,389 2,556,743
7 1,425,500 139,748 1,565,248 1,172,108 138,839 1,310,947 1,719,556 36,498 1,756,055 2,685,508 45,221 2,730,728
8 1,493,481 142,169 1,635,650 1,241,773 141,260 1,383,033 1,877,215 36,902 1,914,117 2,851,940 46,028 2,897,967
MCGR: magnetically controlled growing rod; TGR: traditional growing rod; HKD: Hong Kong Dollar.
Table 3. Accumulative direct, indirect, and total costs for each growing rod strategy.
Year
after
initial
surgery
MCGR (Reop in 2 years)
in $HKD
MCGR (Reop in 3 years)
in $HKD
TGR (Reop in 1 year)
in $HKD
TGR (Reop in 6 months)
in $HKD
Direct
cost
Indirect
cost
Total
cost
Direct
cost
Indirect
cost
Total
cost
Direct
cost
Indirect
cost
Total
cost
Direct
cost
Indirect
cost
Total
cost
1 385,134 3970 389,104 385,134 3970 389,104 201,109 1737 202,846 376,565 3226 379,790
2 459,165 6861 466,026 459,165 6861 466,026 485,860 3182 489,042 827,827 6116 833,943
3 797,518 10,603 808,120 536,168 9667 545,835 766,911 4585 771,497 1,270,161 8923 1,279,084
4 866,924 13,328 880,252 859,343 13,300 872,643 1,046,426 5948 1,052,374 1,699,679 11,648 1,711,327
5 1,176,795 16,855 1,193,649 925,177 15,946 941,123 1,316,376 7271 1,323,646 2,123,412 14,293 2,137,705
6 1,248,940 19,423 1,268,363 995,139 18,514 1,013,653 1,585,698 8555 1,594,253 2,539,881 16,861 2,556,743
7 1,542,500 22,748 1,565,248 1289,108 21,839 1,310,947 1,747,084 8970 1,756,055 2,713,036 17,693 2,730,728
8 1,610,481 25,169 1,635,650 1358,773 24,260 1,383,033 1,904,743 9374 1,914,117 2,879,468 18,500 2,897,967
MCGR: magnetically controlled growing rod; TGR: traditional growing rod; HKD: Hong Kong Dollar.
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studies. Although larger scale studies have reported the
complication rates of the TGR2 (81/140: 58%) and
MCGR32 (11/26: 42.3%) separately, the estimates in these
studies provide very indirect comparisons between the two
techniques. Direct comparisons are preferred over unad-
justed indirect comparisons with estimates from separate
studies.33,34 Hence, without a meta-analysis incorporating
all direct and indirect comparisons, the current study by
Teoh et al.25 is the best available evidence for our purposes.
Despite the high complication rates used for analysis, from
the authors’ experience, the complication rate of the
MCGR is no less than TGR over the entire course of the
EOS treatment. Hence, having similar TGR and MCGR
complication rate parameters for our model creation is a
more realistic representation than the previous cost
analyzes.22–24
MCGR aside, calculations of other implant costs were
based on references provided by Medtronic® for the CD
Horizon® LegacyTM instrumentation system. Although the
cost is subject to variations between different countries of
origin and users with different instrumentation strategies,
this is the cheapest system available to us and can help limit
the effect of implant variability on our model. Despite dif-
ferences in accumulative costs with user variations, this
system is used for both our TGR and MCGR strategies and
thus should still be a viable cost comparison for others to
use as a reference regardless of the health-care system.
One of the major interuser variations in the MCGR is the
frequency of distractions that can cause a rift between the
costs to the public health-care system and to the patients/
family with each year of growing rod treatment. While our
model suggests that the MCGR is cost saving compared to
the TGR in terms of accumulative costs and monetary
expenses with respect to the health-care system, a higher
cost is incurred by the patient and family. The yearly
patient costs with MCGR treatment may be almost 4 times
the patient cost with TGR. This is likely caused by the
increased indirect costs of time away from work for par-
ents, clinic visits, and transportation. At the end of the 8-
year treatment period, the accumulative institutional cost is
reduced 1.9 times, whereas the patient cost increased by 3.1
times when comparing a 2-year MCGR exchange strategy
with a 6-monthly TGR distraction strategy. Yet, this is
based on the authors’ practice of performing outpatient
distractions on a monthly basis. There are other users who
perform distractions every 3-monthly, 4-monthly, or even
6-monthly. It is reasonable to expect this cost to be reduced
with less distraction frequencies. However, our setting in
Hong Kong allows for monthly distractions as patients need
to travel only relatively short distances to the hospital for
these distraction procedures. In other regions, such as those
who include care for the rural population, the travel time
may inhibit the availability of a monthly distraction ser-
vice. It may also be possible to provide these patients with
their own External Remote Controller (ERC) if high dis-
traction frequency is considered.
As it is not feasible for these patients to travel far for
frequent distractions, the effect of increased travel
expenses will be countered by reduced distraction fre-
quency. As such, we expect follow-up visits, time off from
Figure 2.Direct costs for each strategy from year 1 to 8 after initial surgery in sensitivity analysis varying time horizon. Error bar refers
to the mean+ 1 SD of direct costs by microsimulation.
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work, and transportation to be of minor impact on the over-
all cost. Furthermore, even with travel expenses controlled,
the overall cost-saving results of the MCGR is unlikely to
change. The only difference will be the point where the
accumulative costs of MCGR and TGR intersect, which
may occur earlier with reduced follow-up visits and time
off work. This indicates that the frequency of distractions
does not significantly influence the overall cost. Whether
the cost-effectiveness is reduced with less distractions how-
ever is unknown and should be addressed in future work.
This relationship is nevertheless only in monetary value,
and it is important for clinicians to realize that the overall
impact on patients cannot be weighed by a cost figure.
Although more clinic visits are required for MCGR treat-
ment, the risks of repeated surgeries can be minimized as
well as the possible mental burden of repeated hospitaliza-
tions, surgery, and subsequent rehabilitation for these vul-
nerable patients.
Several limitations need to be reported in this study.
Despite the robust cost analysis performed in the study, it
may be subject to management variations in other countries
and with different implantation systems and distraction
methodology. It is also important to emphasize that our
model is a government-based public health-care system
that is different from insurance-based systems. However,
the results generated from our model is a pure and unbiased
unit for unit representation of the actual costs incurred
separately by the health-care system and the patient. More-
over, it is based on a wide breadth of cost unit parameters
with an appropriate complication rate comparison between
the TGR andMCGR. Hence, it is applicable for referencing
in other settings. The evidence regarding complication
rates with the MCGR is scarce however and should be
revisited in the future. Hence, we can only base our risk
calculation on the limited available evidence and the
authors’ experience. There may be some criticism over
inclusion of MCGR fracture as a possible complication.
A change in the welding procedure of the actuator from a
pulsed laser to a continuous laser may have dealt with the
weak points in the rod that led to these fractures. However,
this change was only made in 2012 and further follow-up
data are required to verify this. In addition, health services
utilized in each year for both groups were not supported by
real-life observational or clinical trial data. Nevertheless,
most of the episodes reported are based upon the experi-
ence of the authors who have the longest experience of
managing EOS patients with the MCGR, including subjects
who have completed the entire length of treatment from
implantation until maturity. The information regarding the
time spent on treatment and transportation were also based
on the experience of the authors. There are some concerns
over the use of costing-analysis design, also named cost-
minimization analysis, wherein the health benefits and
effectiveness have not fully been accounted for in this
model. Negative impacts due to surgical complications
were accrued to direct costs but not transferred to the loss
of health effectiveness in term of quality of life. Equal
clinical efficacy between two groups was the key assump-
tion of our model and widely adopted in other costing
models because of the lack of good quality comparative
evidence.30
Conclusions
This simulation cost-analysis study suggests that the
MCGR is cost saving compared to the TGR, and this is
based on an 8-year treatment duration from the perspec-
tives of health-care provider and society, bringing impor-
tant health service implications to decision makers.
Although the accumulative cost of the MCGR is more than
the TGR within 1 year of implantation, the TGR is costlier
at year 2 but its cost-saving potential is only observed from
year 4 onward due to the increased frequency of surgery.
Thus, the MCGR has a modest cost-saving benefit as com-
pared to TGR in the management of EOS patients. Based
on the available evidence and the authors’ long-term
experience in managing EOS patients with MCGR, this
model is a more accurate and detailed representation of the
actual cost incurred with regard to the breadth of cost unit
parameters, rod exchange timing, and complication costs.
This model has helped to investigate the cost-saving benefit
of MCGR and has taken into account the perspectives of
the clinicians, parents, and patients and the health-care sys-
tem as a whole. With improved knowledge of the expecta-
tions with long-term use of the MCGR with regard to
complication and outcomes, better constructed cost-
effectiveness studies can be performed.
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